Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986012 plus carboplatin, etoposide, and nivolumab versus carboplatin, etoposide, and nivolumab in first-line extensive-stage small cell lung cancer
NL-OMON59308Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Atigotatug in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 3 more. Started Jun 2021; status: completed.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON59308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59308.